Hepatitis C News and Research

Latest Hepatitis C News and Research

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C.

23 Nov 2010

ViiV Healthcare awards $20 million to Idenix for GSK2248761 clinical milestone

Idenix Pharmaceuticals, Inc, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the Company will receive a payment of $20 million from the ViiV Healthcare Company for the achievement of a clinical milestone relating to GSK2248761.

23 Nov 2010

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that data demonstrating preclinical efficacy of Chimerix's lead antiviral compound CMX001 against herpes simplex virus (HSV) as well as its ability to penetrate the blood-brain barrier was published in the November 15, 2010 issue of The Journal of Infectious Diseases.

23 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

'Vulnerably housed' people have same severe health problems as homeless people

For every one person in Canada who is homeless, another 23 live in unsafe, crowded or unaffordable housing, meaning the country's housing crisis is even worse than previously thought, according to Dr. Stephen Hwang of St. Michael's Hospital in Toronto.

20 Nov 2010

Quercetin in Gene-Eden may be beneficial against flu virus: Research

Recently, researchers discovered that quercetin, a key ingredient in the natural antiviral supplement Gene-Eden, may be beneficial against the flu virus.

20 Nov 2010

HRSA awarded $1.6M in grants to support Hepatitis C Treatment Expansion Initiative

The Health Resources and Services Administration has awarded $1.6 million in grants to support the Hepatitis C Treatment Expansion Initiative. The funds will aid organizations implementing effective, focused interventions designed to increase access to and completion of Hepatitis C treatment for HIV-positive patients.

20 Nov 2010

Tackling physical, mental health of prisoners would improve public health, researchers say

Providing the more than 10 million people incarcerated around the world "with better health care could prevent outbreaks of HIV and tuberculosis from spilling over into the general population experts say," the Associated Press/Washington Post reports.

20 Nov 2010

Despite progress in testing Americans for HIV, lack of federal/private insurance impedes expansion

With projections that human immunodeficiency virus (HIV) infection rates are increasing in some populations, former Surgeon General Dr. C. Everett Koop -- who charted the nation's policies on HIV/AIDS following the first deaths from AIDS in 1981 -- today issued a stern warning to the public health community: HIV/AIDS continues to be a major epidemic and requires a national mobilization to identify and provide immediate care for many Americans with HIV who remain undiagnosed -- an estimated 200,000 people.

18 Nov 2010

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses.

18 Nov 2010

Medivir AB reports positive interim data on Phase 2b ASPIRE study for hepatitis C

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases announces today positive top-line 24-week interim data from the Phase 2b ASPIRE (C206) study of TMC435 in treatment-experienced hepatitis C patients.

18 Nov 2010

Chimerix’s lipid-conjugated drugs reduces nephrotoxicity: Study

Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.

17 Nov 2010

Cyplasin selects Aurobindo Pharma to supply API component for Ribavirin drug

Cyplasin Biomedical is a product-oriented, specialty pharmaceutical company focused on developing products for the multi-billion dollar hepatitis C virus (HCV) market. The Company is pleased to announce that it has selected Aurobindo Pharma located in Hyderabad , India to supply the active pharmaceutical ingredient (API) component for its Ribavirin drug product called C-Virin.

15 Nov 2010

Biostar third quarter net income increases 9.8% to $3.4 million

Biostar Pharmaceuticals, Inc., Xianyang-based manufacturer of a leading over-the-counter Hepatitis B medicine, Xin Aoxing Oleanolic Acid Capsules, and a variety of pharmaceutical products, today announced financial results for the third quarter ended September 30, 2010.

15 Nov 2010

Unilife and IMCO enter exclusive marketing program for Unitract range of 1mL safety syringes

Unilife Corporation today announced that it has commenced U.S. sales of its Unitract® range of 1mL safety syringes.

15 Nov 2010

NanoViricides' optimized FluCide drug candidates reduce viral load in H1N1 influenza virus study

NanoViricides, Inc. reports that its optimized FluCide™ drug candidates achieved dramatic reduction in viral load within the lungs of animals infected with a lethal dose of H1N1 influenza virus.

15 Nov 2010

Sinovac third quarter sales decrease 7% to $9.6 million

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the three-month and nine-month periods ended September 30, 2010.

15 Nov 2010

Immunitor completes V5 Phase IIb imm01 clinical trial enrollment for TB

Immune Network Ltd., advises that its potential acquisition, Immunitor USA Inc., has announced the completion of enrollment in its Phase IIb imm01 clinical trial of V5 in tuberculosis.

15 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010

GPI launches new advocacy coalition to advance embryonic stem cell research in U.S.

The Genetics Policy Institute (GPI) today announced the launch of a new advocacy coalition of 30 organizations to foster public awareness and advance the cause of embryonic stem cell research in the United States.

12 Nov 2010